AI Terminal
Eckert & Ziegler Strahlen- und Medizintechnik AG
Business and Financial Review • May 12, 2017
130_rns_2017-05-12_8406c4ca-3c7a-4f9b-9376-96ed3557bc71.html
Business and Financial Review
Open in ViewerOpens in native device viewer
News Details
Corporate | 12 May 2017 09:22
Eckert & Ziegler invests in capacity expansion for its GalliaPharm(R) production line
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision/Miscellaneous
12.05.2017 / 09:22
The issuer is solely responsible for the content of this announcement.
Press release
Eckert & Ziegler invests in capacity expansion for its GalliaPharm (R) production line
Berlin, Germany, May 12, 2017 – Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), signed a supply contract for components for a manufacturing line today, paving the way for the creation of additional capacities for its approved GalliaPharm (R) Germanium-68/Gallium-68 generator. Following the approval of the NETSPOT (R) kit (tumor diagnostic agent) in the USA and SOMAKIT TOC (R) within the EU, demand for pharmaceutical generators has significantly increased.
“The capacity expansion is part of a more broadly based investment program. We are not only enhancing our production capacity but also focusing particularly on ensuring availability of the currently limited active substance. This way, supply of diagnostic agents for patients and the increasing number of clinical trials using Ga-68-based tracers is guaranteed. In addition, we are expanding our capacities to take back expired generators and transfer them towards duly disposal procedures”, explained Dr. André Heß, Executive Board member at Eckert & Ziegler AG with responsibility for the Radiopharma segment.
The investment is linked to a strengthened strategic focus on theranostic applications. The related products, primarily based on Gallium-68, Yttrium-90 and Lutetium-177 are used for diagnostic and therapeutic purposes of various conditions. Intensifying development of radiopharmaceutical formulations, test batch production of radiopharmaceuticals for clinical trials and initiating cooperation with young, aspiring pharmaceutical companies are additional intentions in the near future.
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) employs around 610 people and is one of the world’s largest providers of isotope technology components for radiation therapy and nuclear medicine.
Contributing to saving lives.
Your contacts for inquiries:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
Eckert & Ziegler Radiopharma GmbH, Franziska Held/Jan Schöpflin, Marketing
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-252, [email protected], www.radiopharma.com
12.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | 49 30 941084-138 |
| Fax: | 49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Tradegate Exchange |
| End of News | DGAP News Service |